ThreatConnect Releases Risk Quantifier™ 6.0 — Driving Continued Innovation in Cyber Risk Quantification
18.10.2021 13:30:00 EEST | Business Wire | Press release
ThreatConnect Inc.®, the leader in reducing complexity and enabling better decision making in cybersecurity, today released ThreatConnect Risk Quantifier™ 6.0 (RQ 6.0), continuing its innovation in the emerging field of cyber risk quantification.
ThreatConnect Risk Quantifier™ (RQ) enables companies to see the financial risks they face from cyber attacks and also prioritize investments that provide the best ROI. RQ’s calculations are informed by your internal environment, threat intelligence, vulnerability management, operations and response data found within ThreatConnect and other integrations. RQ is distinctly different from other approaches offered in the market as it focuses on automation and data integration, and delivers value in days and weeks as opposed to months and years.
With RQ 6.0 organizations that are looking at financial cyber risk quantification will have the option of leveraging full FAIR scenario’s, using semi-automated FAIR scenario’s, and full automation in one platform.
FAIR is an internationally known standard that has helped companies with awareness and understanding of cyber risk quantification. Organizations implementing FAIR in their CRQ programs have struggled with subjectivity, speed, and actionability, which is why RQ 6.0 is introducing semi-automated FAIR scenario’s that automate a large portion of FAIR in order to reduce complexity and increase time to value for customers.
Semi-Automated FAIR scenarios tackle one of the most challenging aspects of cyber risk quantification - calculating Loss Event Frequency and it’s piece parts. RQ combines data from inside the organization with its own models to evaluate attacker capability against defender strength. Applying this automated calculation to FAIR provides actionable, data-driven results within the FAIR framework and helps organizations transform their manual processes into the scalable, defensible needed to manage the complex risks they face.
“We’ve heard from customers, partners and the broader industry that solutions are needed to address the challenges in adopting and benefiting from CRQ programs,” said ThreatConnect Vice President of Cyber Risk Strategy Gerald Caponera. “Now, through the automation of part of FAIR, organizations can quickly adopt and advance their CRQ programs using their own data combined with ThreatConnect’s analytical capabilities.”
Using a risk-led approach to cybersecurity makes prioritization easy for security teams, enabling them to filter out noise and focus on what matters most. With CRQ, TIP and SOAR capabilities combined, ThreatConnect unifies the actions of the security team around the most critical risks, supports their response with streamlined and automated workflows and strengthens the entire security ecosystem through powerful technology integrations.
Additional details of the release are further outlined in a new blog and video available on the ThreatConnect web site. For more information – click here.
About ThreatConnect
ThreatConnect, Inc. provides cybersecurity software that reduces complexity for everyone, makes decision making easy by turning intelligence into action, and integrates processes and technologies to continually strengthen defenses and drive down risk. Designed by analysts but built for the entire team (security leadership, risk, security operations, threat intelligence, and incident response), ThreatConnect’s decision and operational support platform is the only solution available today with cyber risk quantification, intelligence, automation, analytics, and workflows in one. To learn more about our Cyber Risk Quantification, Threat Intelligence Platform (TIP) or Security Orchestration, Automation, and Response (SOAR) solutions, visit www.ThreatConnect.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005045/en/
Contact information
Levick U.S.
Maria Stagliano
Phone: +1 202.973-5341
ThreatConnect@levick.com
Lewis U.K.
Jessica Collings
Phone: +44 207.802.2626 | Fax: +44 207.802.2627
hellolondon@teamlewis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release
Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
